Integrated Biopharma, Inc.
INBP
$0.3069
$0.01194.03%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 341.04% | 841.38% | 429.41% | -108.17% | -117.49% |
| Total Depreciation and Amortization | 5.00% | 5.34% | 5.81% | 12.64% | 23.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 142.28% | 41.51% | -14.49% | 145.39% | 144.23% |
| Change in Net Operating Assets | 59.65% | -3,285.00% | -146.36% | -143.87% | -174.52% |
| Cash from Operations | 1,106.52% | -81.52% | -23.46% | -101.11% | -105.32% |
| Capital Expenditure | -500.00% | -449.04% | -376.72% | -219.55% | 63.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -100.00% | -100.00% |
| Cash from Investing | -506.32% | -476.77% | -398.20% | -228.68% | 62.89% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 31.71% | 4.88% | 69.12% | 98.14% | 98.14% |
| Issuance of Common Stock | 38.46% | -100.00% | -- | -51.85% | -51.85% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 64.29% | -39.29% | 78.68% | 98.97% | 99.11% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 589.80% | -122.65% | -63.35% | -122.47% | -138.24% |
